AHCC® Clinical Evidence: A PharmD’s Research Review

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

Why I Built This Reference Library

AHCC is one of the most misunderstood supplements I encounter in practice. Patients either have not heard of it at all, or they have found it through cancer forums and come in with unrealistic expectations. The research is worth reading carefully — and that is exactly what this library is for.

This is my personally curated, evidence-labeled reference library. Every citation has been individually verified. I distinguish between human clinical trials, preclinical/laboratory research, and scientific reviews so you can evaluate the strength of the evidence yourself.

If you want to discuss whether AHCC is appropriate for your specific health situation, call us at (408) 622-8068 or send us a message. A free pharmacist consultation is always available.

What Is AHCC?

AHCC (Active Hexose Correlated Compound) is a standardized cultured Lentinula edodes mycelial extract developed in Japan. It has been evaluated in human clinical studies, preclinical research, and scientific reviews examining immune-related biomarkers, persistent HPV infection, supportive oncology outcomes, and other research questions. Its composition includes partially acetylated alpha-glucans and other constituents that have been investigated for potential immune-modulating effects.

As a pharmacist, I discuss AHCC with patients who are interested in evidence-based approaches to nutritional immune support, while considering the individual's medications, health conditions, treatment goals, and available clinical evidence. Fucoidan has also been independently investigated for immune-related effects, and some formulations combine the two ingredients; however, human clinical evidence specifically evaluating the combination remains limited. You can explore the NatureMedic Fucoidan + AHCC products we carry.

Immune Function and General Immunity

1. HUMAN RCT
   Terakawa N, et al. Immunological Effect of AHCC in Healthy Volunteers: A Double-Blind, Placebo-Controlled Trial. PMID: 18791928

   Randomized placebo-controlled trial (n=21); AHCC 3 g/day for 4 weeks increased selected dendritic-cell measures, while NK-cell activity and measured cytokines did not significantly differ from placebo.

2. HUMAN RCT
   Roman BE, et al. Short-term Supplementation with AHCC Improves Antibody Response to Influenza B Vaccine. PMID: 23351405

   Pilot randomized trial (n=30); AHCC 3 g/day was associated with higher influenza-B antibody responses after seasonal influenza vaccination. The study was small and further confirmation is needed.

3. HUMAN STUDY
   Yin Z, Fujii H, Walshe T. Effects of AHCC on Immune Function in Healthy Adults Aged 50 Years and Over. PMID: 20732368

   Human study in healthy adults aged 50 years or older examining T-cell immune markers; selected IFN-γ/TNF-α-producing CD4+ and CD8+ T-cell populations increased during AHCC intake. These were biomarker outcomes rather than clinical disease outcomes.

4. HUMAN STUDY
   Takanari J, et al. Effects of AHCC on Immune and Stress Responses in Healthy Individuals. PMID: 29558822

   Small exploratory human studies examined autonomic stress responses, sleep-related measures, and NK-cell activity. Findings should be considered preliminary because of very small sample sizes and heterogeneous study designs.

5. HUMAN RCT
   Chowdhury AH, et al. Modulation of T Regulatory and Dendritic Cell Phenotypes Following Ingestion of AHCC. PMID: 31618905

   Randomized mechanistic study (n=40 healthy men) comparing placebo, Bifidobacterium longum BB536, AHCC, and their combination during azithromycin exposure; regulatory T-cell and dendritic-cell phenotypes were evaluated. Findings were exploratory and do not establish a standalone clinical benefit of AHCC.

6. PRECLINICAL
   Olamigoke L, et al. AHCC Activation and Selection of Human Lymphocytes. PMID: 26788109

   Laboratory study examining AHCC's effects on human lymphocyte activation and subset selection in cell culture; findings are mechanistic and do not establish immune clinical benefits in humans.

7. REVIEW
   Shin MS, et al. The Effects of AHCC on Natural Killer and T Cells in Health and Disease. PMID: 31930148

   Narrative review summarizing preclinical and clinical evidence on AHCC's effects on NK-cell and T-cell populations across healthy and disease contexts; conclusions are limited by the heterogeneity of underlying studies.

HPV and Persistent High-Risk Viral Infections

8. HUMAN RCT
   Smith JA, et al. AHCC Supplementation to Support Immune Function to Clear Persistent HPV Infections. PMID: 35814366

   Phase II randomized, double-blind, placebo-controlled trial in women >30 years with persistent high-risk HPV infection for >2 years. AHCC 3 g/day for 6 months was associated with a higher proportion becoming HPV DNA/RNA negative than placebo; 9 of 14 initial AHCC responders remained negative 6 months after stopping supplementation. The study was small and requires independent replication.

9. HUMAN + PRECLINICAL
   Smith JA, et al. From Bench to Bedside: Evaluation of AHCC to Modulate Host Immunity to Clear High-Risk HPV. PMID: 30949451

   Translational study combining laboratory and animal experiments with two small human pilot studies of persistent high-risk HPV. Preliminary human findings supported further investigation of AHCC, but the uncontrolled pilot data were insufficient to establish efficacy and preceded the later randomized Phase II trial.

10. COMMENTARY
    Gau VL, Benninger MS. Potential Role for AHCC in Treatment of Recurrent Respiratory Papillomatosis. PMID: 35773058

    Editorial discussing a potential role for AHCC in recurrent respiratory papillomatosis; it does not report a controlled AHCC clinical trial and should not be considered efficacy evidence.

11. COMMENTARY
    Farasatinasab M, Nassiri S. Could AHCC Be an Appropriate Choice to Clear HPV Infection? PMID: 35775905

    Commentary discussing existing AHCC and HPV research; it does not provide new clinical efficacy data.

Other Viral / Hypothesis Literature

12. COMMENTARY
    Di Pierro F, et al. Possible Therapeutic Role of AHCC in Patients Infected with 2019 Novel Coronavirus. PMID: 32162896

    Hypothesis/commentary published early in the COVID-19 pandemic; it does not provide clinical evidence that AHCC prevents or treats COVID-19.

Cancer Support and Oncology

13. HUMAN RCT
    Suknikhom W, et al. Effects of AHCC on CD4+ and CD8+ Levels in Patients with Ovarian Cancer Receiving Platinum-Based Chemotherapy. PMID: 28440968

    Randomized controlled trial in 28 evaluable patients with epithelial ovarian or peritoneal cancer receiving platinum-based chemotherapy; AHCC 3 g/day did not significantly improve the primary changes in CD4+ or CD8+ T-cell levels versus placebo. CD8+ levels were higher with AHCC at the sixth chemotherapy cycle, while bone-marrow suppression and overall quality of life did not significantly differ between groups; nausea and vomiting were reported less frequently with AHCC.

14. HUMAN STUDY
    Ito T, et al. Reduction of Adverse Effects by AHCC in Patients with Advanced Cancer During Chemotherapy. PMID: 24611562

    Small clinical study (n=24) in patients with advanced cancer receiving chemotherapy; patients completed one chemotherapy cycle without AHCC followed by a second cycle with AHCC. During AHCC use, investigators reported improvements in selected quality-of-life measures, hematologic and hepatic toxicity measures, and salivary HHV-6 DNA levels. Because the study lacked a concurrent randomized control group, these findings are preliminary and do not establish that AHCC reduces chemotherapy-related adverse effects.

15. PRECLINICAL
    Park HJ, et al. AHCC Promotes Anti-Tumor Effect of Dual Immune Checkpoint Blockade in Murine Colon Cancer. PMID: 35514996

    Mouse model study; AHCC combined with dual immune checkpoint blockade showed enhanced antitumor activity in murine colon cancer. These are animal findings and do not establish human antitumor efficacy.

16. PRECLINICAL
    Choi JY, et al. AHCC Inhibits Proliferation of Ovarian Cancer Cells by Suppressing STAT3 Activation. PMID: 29111786

    Cell culture study; AHCC suppressed STAT3 signaling and inhibited proliferation in ovarian cancer cell lines. These are mechanistic in vitro findings and do not establish human antitumor efficacy.

17. PRECLINICAL
    Mathew L, et al. Evaluation of AHCC in Combination with Anticancer Hormones in Orthotopic Breast Cancer Models. PMID: 28438054

    Preclinical breast-cancer study evaluating AHCC with tamoxifen or letrozole; findings suggested a possible interaction signal with letrozole in one experimental model. These findings do not establish a clinically meaningful drug–supplement interaction, but they support caution and further study when AHCC is used with endocrine therapy.

18. PRECLINICAL
    Ignacio RM, et al. Therapeutic Effect of AHCC Combined with CpG-ODN in B16 Melanoma Murine Model. PMID: 26082022

    Mouse model study; AHCC combined with CpG-ODN immunostimulant showed antitumor activity in a murine melanoma model. These are animal findings and do not establish human antitumor efficacy.

19. PRECLINICAL
    Fatehchand K, et al. AHCC Enhances Extrinsic-Pathway-Mediated Apoptosis of Acute Myeloid Leukemic Cells. PMID: 28727820

    Study combining primary human AML patient samples and an in-vivo mouse AML model; AHCC promoted extrinsic apoptotic pathway activity and showed antileukemic effects in both settings. While the use of primary human samples adds translational relevance beyond standard cell-line work, these findings remain preclinical and do not establish human antitumor efficacy.

20. PRECLINICAL
    Haidari M, et al. Disruption of Endothelial Adherens Junction by Invasive Breast Cancer Cells Is Attenuated by AHCC. PMID: 24211779

    Cell culture study; AHCC attenuated disruption of endothelial junctions by invasive breast cancer cells, suggesting a potential mechanistic role in limiting cancer cell invasion. These are in vitro findings and do not establish human antitumor efficacy.

21. SYSTEMATIC REVIEW
    Ulbricht C, et al. An Evidence-Based Systematic Review of AHCC by the Natural Standard Research Collaboration. PMID: 23931762

    Systematic review synthesizing available AHCC research across multiple health conditions; reflects the evidence base available at time of publication and should be read in the context of subsequent studies.

Oncology / Mechanistic and Chemoprevention Research

22. PRECLINICAL
    Graham EA, et al. MicroRNA Signature in Chemoprevention of Stem and Progenitor Pools by AHCC. PMID: 28886271

    Preclinical study examining microRNA expression patterns in stem and progenitor cell populations following AHCC exposure; findings suggest potential chemopreventive mechanisms at the molecular level. These are laboratory observations and do not establish chemopreventive efficacy in humans.

23. PRECLINICAL
    Takahashi M, et al. Activation of NF-E2-related Factor-2 and Inhibition of Intestinal Tumor Development by AHCC. PMID: 31777421

    Preclinical study in a rodent intestinal tumor model; AHCC activated the Nrf2 antioxidant pathway and was associated with reduced intestinal tumor development. These animal findings identify a potential mechanistic pathway but do not establish cancer-preventive effects in humans.

Pancreatic Cancer and Chemotherapy Support

24. HUMAN STUDY
    Yanagimoto H, et al. Alleviating Effect of AHCC on Chemotherapy-Related Adverse Events in Pancreatic Ductal Adenocarcinoma. PMID: 26847832

    Prospective controlled study in 75 patients with unresectable pancreatic ductal adenocarcinoma receiving gemcitabine; patients taking AHCC 6 g/day for 2 months had smaller changes in selected inflammatory and nutritional measures (CRP elevation, albumin decline) and less frequently reported taste disorder than controls. Grade 3 mGPS occurred less often in the AHCC group. Because AHCC exposure was not randomly assigned, these findings are preliminary and do not establish that AHCC prevents chemotherapy-related adverse effects.

25. HUMAN STUDY
    Hashimoto D, et al. Nutritional Impact of AHCC for Pancreatic Cancer Patients Treated with Neoadjuvant Therapy. PMID: 34086127

    Observational study examining nutritional and body-composition outcomes in pancreatic cancer patients receiving neoadjuvant therapy with AHCC supplementation. Findings are preliminary and do not establish a causal nutritional benefit.

26. HUMAN RCT
    Okuno M, et al. Efficacy of Lentinula edodes Mycelia Extract on Chemotherapy-Related Taste Disorders in Pancreatic Cancer Patients. PMID: 35950537

    Randomized, double-blind, placebo-controlled trial in 98 patients with pancreatic ductal adenocarcinoma receiving chemotherapy; AHCC did not significantly reduce the study's primary anemia endpoint compared with placebo. Taste disorders occurred less frequently and selected nutritional measures improved with AHCC, supporting further investigation of these supportive-care outcomes.

27. PROTOCOL
    Hashimoto D, et al. Efficacy of AHCC on Survival of Patients with Resectable Pancreatic Cancer: Phase II Protocol. PMID: 35151367

    Registered Phase II trial protocol; this citation describes a planned study design and does not report outcomes. Results are not yet available from this registration.

Mechanistic / Preclinical Pancreatic Cancer Research

28. PRECLINICAL
    Islam S, et al. AHCC Downregulates Cortactin in Gemcitabine-Resistant Pancreatic Cancer Cells. PMID: 34386076

    Cell culture study in gemcitabine-resistant pancreatic cancer cells; AHCC reduced cortactin expression and cell migration. These mechanistic in vitro findings do not establish antimetastatic activity in patients.

29. PRECLINICAL
    Nawata J, et al. AHCC Down-Regulates SOX2 of Pancreatic Cancer Cells. PMID: 25202061

    Cell culture study in gemcitabine-resistant pancreatic cancer cells; AHCC reduced expression of the tumor-associated transcription factor SOX2. These mechanistic findings do not establish clinical anticancer efficacy.

30. PRECLINICAL
    Suenaga S, et al. AHCC Down-Regulates HSP27 and Enhances Gemcitabine Cytotoxicity. PMID: 24403454

    Cell culture study in gemcitabine-resistant pancreatic cancer cells; AHCC reduced HSP27 expression and enhanced gemcitabine cytotoxicity in vitro. This laboratory finding does not establish that AHCC improves gemcitabine effectiveness in patients.

31. PRECLINICAL
    Kuhara K, et al. CDCP1 Is Down-Regulated by AHCC in Human Pancreatic Cancer Cells. PMID: 30396925

    Cell culture study in gemcitabine-resistant pancreatic cancer cells; AHCC reduced expression of CDCP1, a protein associated with cancer invasion and metastasis. These mechanistic findings do not establish clinical antimetastatic efficacy.

32. PRECLINICAL
    Tokunaga M, et al. AHCC Down-Regulates HSF1 in Gemcitabine-Resistant Pancreatic Cancer Cells. PMID: 26504030

    Cell culture study in gemcitabine-resistant pancreatic cancer cells; AHCC reduced HSF1 expression, a transcription factor involved in HSP27 regulation. This mechanistic finding does not establish clinical anticancer efficacy.

Liver Health

33. HUMAN RCT
    Kim H, et al. Effect of AHCC in Alcohol-Induced Liver Enzyme Elevation. PMID: 25744424

    Randomized controlled study in participants with mildly elevated alcohol-associated liver enzymes; AHCC 1 g/day or 3 g/day for 12 weeks was associated with changes in ALT and selected inflammatory biomarkers compared with placebo. These findings concern laboratory markers and do not establish that AHCC prevents or treats chronic liver disease.

34. HUMAN STUDY
    Matsui Y, et al. Improved Prognosis of Postoperative Hepatocellular Carcinoma Patients When Treated with Functional Foods: A Prospective Cohort Study. PMID: 12076865

    Prospective cohort study of 269 patients following surgical resection of hepatocellular carcinoma; 113 received AHCC. The AHCC group showed longer recurrence-free time and overall survival in multivariable analyses. Because AHCC exposure was not randomized, the study cannot establish that AHCC caused the observed reductions in recurrence or mortality.

35. HUMAN STUDY
    Cowawintaweewat S, et al. Prognostic Improvement of Patients with Advanced Liver Cancer After AHCC Treatment. PMID: 16913187

    Small prospective cohort study (n=44) in patients with advanced liver cancer; 34 patients received AHCC and 10 served as controls. Longer survival and improvements in selected quality-of-life measures were reported in the AHCC group. Because the study was small and nonrandomized with unequal groups, it cannot establish that AHCC caused the observed survival benefit.

36. HUMAN STUDY
    Kamiyama T, et al. Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With AHCC. PMID: 35075934

    Single-arm, open-label study of 29 patients receiving AHCC 3 g/day for up to 2 years after curative surgery for hepatocellular carcinoma; investigators reported recurrence-free survival and favorable safety observations during follow-up. Because the study was uncontrolled and nonrandomized, it cannot establish that AHCC prevents hepatocellular carcinoma recurrence.

37. PRECLINICAL
    Tanaka Y, et al. Adenosine, a Hepato-Protective Component in AHCC: Identification and iNOS Suppression Mechanism. PMID: 24878381

    Preclinical mechanistic study using cultured rat hepatocytes; adenosine was identified as one AHCC component that suppressed inducible nitric oxide synthase (iNOS) expression and nitric oxide production. These laboratory findings suggest a potential mechanism but do not establish liver-protective effects in humans.

Gut and Intestinal Immunity

38. PRECLINICAL
    Mallet JF, et al. AHCC Promotes Intestinal Immune Response Involving TLR-2 and TLR-4 in BALB/c Mice. PMID: 25596849

    Preclinical study combining BALB/c mice and primary intestinal epithelial-cell experiments; AHCC altered intestinal immune markers, including IgA and selected cytokines, with laboratory findings implicating TLR-2 and TLR-4 signaling. These findings do not establish effects on intestinal immunity or disease outcomes in humans.

39. PRECLINICAL
    Daddaoua A, et al. AHCC Has Direct Immunomodulatory Actions on Intestinal Epithelial Cells. PMID: 23194525

    Cell culture study examining intestinal epithelial cells and monocyte-derived cells; AHCC induced selected cytokine responses through signaling pathways involving TLR4/MyD88 and NF-κB/MAPK. These mechanistic findings do not establish gastrointestinal or immune benefits in humans.

40. PRECLINICAL
    Mascaraque C, et al. AHCC Exerts Therapeutic Effects in Lymphocyte-Driven Colitis. PMID: 25186628

    Mouse study using a T-cell-driven experimental colitis model; AHCC reduced selected inflammatory and biochemical measures and altered inflammatory cytokine signaling. These animal findings do not establish that AHCC prevents or treats inflammatory bowel disease in humans.

41. PRECLINICAL
    Ocon B, et al. AHCC and Bifidobacterium longum BB536 Exert Symbiotic Effects in Experimental Colitis. PMID: 22941198

    Rat study using chemically induced experimental colitis; AHCC and Bifidobacterium longum BB536 showed anti-inflammatory effects, with stronger effects on selected measures when used together. These preclinical findings do not establish clinical synergy or efficacy for inflammatory bowel disease in humans.

Infectious Disease and Host-Response Research

42. PRECLINICAL
    Tena-Garitaonaindia M, et al. Lentinula edodes Cultured Mycelium Inhibits Pseudomonas aeruginosa Infectivity Mechanisms. PMID: 35369436

    Laboratory study demonstrating that standardized Lentinula edodes cultured mycelium (the AHCC source material) interfered with several Pseudomonas aeruginosa virulence and infectivity mechanisms in cell culture models. These are in vitro host-response findings and do not establish antimicrobial efficacy in humans.

43. PRECLINICAL
    Perez-Cantero A, et al. Increased Efficacy of Oral Amphotericin B and AHCC Against Aspergillosis. PMID: 31484389

    Animal model study evaluating AHCC combined with oral amphotericin B in a preclinical aspergillosis model; the combination showed greater antifungal activity than either agent alone. These are animal findings examining host–pathogen interaction and do not establish that AHCC improves antifungal outcomes in humans.

Safety, Tolerability, Toxicology, and Drug Interactions

44. HUMAN STUDY
    Spierings ELH, Fujii H, Sun B, Walshe T. A Phase I Study of the Safety of AHCC in Healthy Volunteers. PMID: 18202543

    Phase I safety and tolerability study in 26 healthy adults receiving AHCC 9 g/day for 14 days. Two participants discontinued because of nausea or intolerance, and mild transient adverse effects included gastrointestinal symptoms, headache, fatigue, and muscle cramps; no significant laboratory abnormalities were reported. This short-duration study supports tolerability at the studied dose but does not establish long-term safety or safety in medically complex populations.

45. PRECLINICAL
    Fujii H, et al. Genotoxicity and Subchronic Toxicity Evaluation of AHCC. PMID: 20951179

    Preclinical genotoxicity and 90-day subchronic toxicity study conducted in rodents; AHCC did not demonstrate genotoxic potential and was well tolerated at tested doses. These preclinical safety findings support but do not substitute for human long-term safety data.

46. HUMAN + PRECLINICAL
    Mach CM, Fujii H, Wakame K, Smith J. Evaluation of Active Hexose Correlated Compound Hepatic Metabolism and Potential for Drug Interactions with Chemotherapy Agents. PMID: 19087767

    In vitro and ex vivo metabolism study evaluating AHCC across several CYP450 pathways using CYP450 assays and a cryopreserved human-hepatocyte model. AHCC did not inhibit CYP3A4, CYP2C8, CYP2C9, or CYP2D6 activity in the experimental systems, but it behaved as a CYP2D6 substrate and showed CYP2D6 induction potential. These findings suggest a possible interaction risk with CYP2D6-metabolized medications, but the clinical magnitude of this effect in humans has not been established.

Products Containing AHCC

The evidence summarized above relates to AHCC as studied in the cited research and should not be interpreted as evidence that any specific finished product has been proven to prevent or treat disease.

At Khang Pharmacy, AHCC is available in the NatureMedic Fucoidan + AHCC line:

• NatureMedic AHCC Capsule (160 capsules)
• NatureMedic AHCC Liquid (50 packets)

Not sure if AHCC is right for you? Call our PharmD at (408) 622-8068 for a free personalized recommendation.

Reviewed by:

Dai Tran, PharmD, MBA, B.S. — View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com